Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

NB003

NB003 Phase 1

Ningbo Newbay Technology Development · Phase 1 · Completed · Enrollment 258

NCT04936178

ArmPopulationDoseEstimandComparatorEfficacy
NB003, 2L to 4L or laterGIST 2L to 4L or later (n = 158)not stated in sourceSingle armn/robjective response rate: 28.5%, data as of March 2025median progression-free survival: 9.2 months, data as of March 2025
NB003, 3L subgroupGIST 3L (n not stated in source)not stated in sourceSingle armn/robjective response rate: 46.7%, data as of March 2025median progression-free survival: 13.7 months, data as of March 2025